 Welcome to Anadrol.com
About This Disease
Many people with chronic (long-term) illnesses, such as cancer*, HIV infection, or renal disease, have a lack of energy or tire easily. There are many possible reasons for this type of feeling, but a common cause is a condition called anemia.
*See Full Prescribing Information. Anadrol-50 (oxymetholone) is contraindicated in: Carcinoma of the prostate or breast in male patients, and Carcinoma of the breast in females with hypercalcemia.
Anadrol®-50 (oxymetholone)
50 mg tablets for anemia
Anadrol-50 is used in the treatment of anemias caused by deficient red cell production. It belongs to a class of drugs called anabolic steroids, which are similar to the male hormone testosterone.
SEE FULL BOXED WARNING FOR MORE INFORMATION ON THESE CONDITIONS IN THE FULL PRESCRIBING INFORMATION.
Anadrol-50 enhances the production and urinary excretion of erythropoietin (EPO, a chemical in your body that can increase the production of new red blood cells), in patients with anemias due to bone marrow failure, and it often stimulates red blood cell production in patients with anemias due to deficient red cell production.
Anadrol-50 is the only oral anabolic steroid that has been approved by the U.S. Food and Drug Administration for the treatment of anemias caused by deficient red blood cell production.
Unlike some other anabolic steroids, which must be injected often, Anadrol-50 is a tablet that is taken by mouth. Also, Anadrol-50 does not replace other supportive measures, but works together with other treatments that your doctor may give you for anemia.
Anadrol-50 is available by prescription only. Ask your doctor if Anadrol -50 is right for you.
SEE FULL BOXED WARNING FOR MORE INFORMATION ON THESE CONDITIONS IN THE FULL PRESCRIBING INFORMATION.
Anadrol-50 should not be used in: male patients with carcinoma of the prostate or breast; females with hypercalcemia with carcinoma of the breast; women who are or may become pregnant; patients with nephrosis or the nephrotic phase of nephritis; patients with hypersensitivity to the drug or with severe hepatic dysfunction.
The following conditions have been reported in patients receiving androgenic anabolic steroids as a general class of drugs:
Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid therapy. These cysts are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with liver failure. They are often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal of drug usually results in complete disappearance of lesions.
Liver cell tumors are also reported. Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have been reported. Withdrawal of drug often results in regression or cessation of progression of the tumor. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening intra-abdominal hemorrhage develops.
Blood lipid changes that are known to be associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. These changes include decreased high-density lipoprotein and sometimes increased low-density lipoprotein. The changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.
Edema may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease.
Insulin or oral hypoglycemic drugs may require dosage adjustments in diabetic patients who receive anabolic steroids.
|
